Completed PHASE1 INTERVENTIONAL 1-arm NCT05856747

A Study to Compare Two Bioanalytical Assays for Tebipenem

An Open-Label, Single-Center, Single-Period Study to Compare Two Bioanalytical Assays for Tebipenem Following Administration of Oral Tebipenem Pivoxil Hydrobromide in Healthy Adult Volunteers

Sponsor: Spero Therapeutics

Conditions Healthy Volunteers

Interventions TBP-PI-HBr

Updated 5 times since 2023 Last updated: Mar 26, 2024 Started: May 4, 2023 Primary completion: Jun 1, 2023 Completion: Jun 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers and is currently completed. Spero Therapeutics leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2024 — Jul 2024 [monthly]

Completed PHASE1
Aug 2023 — Apr 2024 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jun 2023 — Aug 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Spero Therapeutics

Data source: Spero Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Creve Coeur, United States